Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature

Journal of Clinical Psychiatry

Volumn 70, Issue 8, 2009, Pages 1078-1090

  Goldstein, Benjamin I ^a   Kemp, David E ^b   Soczynska, Joanna K ^c   McIntyre, Roger S ^c,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELECOXIB; CYTOKINE; ETANERCEPT; GLUCOCORTICOID; MOOD STABILIZER; PLACEBO; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; PYRAZOLE DERIVATIVE; RISPERIDONE; SULFONAMIDE;

ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG MECHANISM; GENE EXPRESSION; HEADACHE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MANIA; OBESITY; OSTEOPOROSIS; PAIN; PARAMETER; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; BRIEF PSYCHIATRIC RATING SCALE; PHYSIOLOGY; QUESTIONNAIRE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; COMORBIDITY; CYTOKINES; HUMANS; INFLAMMATION; LITHIUM CARBONATE; PYRAZOLES; QUESTIONNAIRES; RISPERIDONE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 70349562518     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08r04505     Document Type: Review

References (156)

1. Smith RS. The macrophage theory of depression. (published correction appears in Med Hypotheses 1991;36:178) Med Hypotheses. 1991;35:298-306. PubMed doi:10.1016/0306-9877(91)90272-Z
2. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201-217. PubMed doi:10.1016/j.pnpbp.2004.11.003
3. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31. PubMed doi:10.1016/j.it.2005.11.006 (Pubitemid 43083561)
4. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63:801-808. PubMed doi:10.1016/j.biopsych.2007.09.024
5. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis. 2006;9(suppl 3):271-276. PubMed (Pubitemid 44253320)
6. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445-452. PubMed doi:10.1001/archpsyc.58.5.445 (Pubitemid 32411324)
7. Barkhudaryan N, Dunn AJ. Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo- pituitary-adrenocortical axis. Neurochem Res. 1999;24:1169-1180. PubMed doi:10.1023/A:1020720722209 (Pubitemid 29413607)
8. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:1-33. PubMed doi:10.1016/S0278-5846(97)00179-6 (Pubitemid 28096427)
9. Aktas O, Ullrich O, Infante-Duarte C, et al. Neuronal damage in brain inflammation. Arch Neurol. 2007;64:185-189. PubMed doi:10.1001/archneur.64.2.185
10. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2001;2:734-744. PubMed doi:10.1038/35094583
11. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "Metabolic Syndrome Type II"? Ann Clin Psychiatry. 2007;19:257-264. PubMed doi:10.1080/10401230701653377
12. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161-174. PubMed
13. Belmaker RH. Bipolar Disorder. N Engl J Med. 2004;351(5):476-486. PubMed doi:10.1056/NEJMra035354
14. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994;31:281-294. PubMed doi:10.1016/0165-0327(94)90104-X
15. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66:1205-1215. PubMed
16. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543-552. PubMed doi:10.1001/archpsyc.64.5.543 (Pubitemid 46718287)
17. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528-2530. PubMed doi:10.1001/jama.293.20.2528
18. Miller AH, Manji HK. On redefining the role of the immune system in psychiatric disease. Biol Psychiatry. 2006;60:796-798. PubMed doi:10.1016/j.biopsych.2006.09.013
19. Tsai SY, Lee CH, Kuo CJ, et al. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry. 2005;66:1586-1591. PubMed
20. Rapaport MH. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord. 1994;32:149-156. PubMed doi:10.1016/0165-0327(94) 90012-4
21. Maes M, Bosmans E, Calabrese J, et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29:141-152. PubMed doi:10.1016/0022-3956(94)00049-W
22. Hornig M, Goodman DBP, Kamoun M, et al. Positive and negative acute phase proteins in affective subtypes. J Affect Disord. 1998;49:9-18. PubMed doi:10.1016/S0165-0327(97)00180-8 (Pubitemid 28139092)
23. Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33:335-340. PubMed doi:10.1016/S0022-3956(99)00007-2 (Pubitemid 29267636)
24. Tsai S-Y, Chen K-P, Yang Y-Y, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45:989-994. PubMed doi:10.1016/S0006-3223(98)00159-0
25. Tsai SY, Yang YY, Kuo CJ, et al. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64:185-193. PubMed doi:10.1016/S0165-0327(00)00252-4
26. Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7:1107-1114. PubMed doi:10.1038/sj.mp.4001084 (Pubitemid 36044270)
27. Su K-P, Leu S-JC, Yang Y-Y, et al. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. (published correction appears in J Affect Disord 2003;73:299) J Affect Disord. 2002;71:205-209. PubMed doi:10.1016/S0165-0327(01)00369-X
28. Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175-179. PubMed doi:10.1002/hup.390
29. Breunis MN, Kupka RW, Nolen WA, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry. 2003;53(2):157-165. PubMed doi:10.1016/S0006-3223(02)01452-X
30. Boufidou F, Nikolaou C, Alevizos B, et al. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82:309-313. PubMed doi:10.1016/j.jad.2004.01.007 (Pubitemid 39370835)
31. Kim Y-K, Myint A-M, Lee B-H, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004;129:267-272. PubMed doi:10.1016/j.psychres.2004.08.005
32. Liu H-C, Yang Y-Y, Chou Y-M, et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150:116-122. PubMed doi:10.1016/j.jneuroim.2004.01.006
33. O'Brien SM, Scully P, Scott LV, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90:263-267. PubMed doi:10.1016/j.jad.2005.11.015 (Pubitemid 43183536)
34. Knijff EM, Breunis MN, van Geest MC, et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006;8:740-750. PubMed doi:10.1111/j.1399-5618.2006.00359.x
35. Dickerson F, Stallings C, Origoni A, et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:952-955. PubMed doi:10.1016/j.pnpbp.2007.02.018 (Pubitemid 46660310)
36. Huang T-L, Lin F-C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:370-372. PubMed doi:10.1016/j.pnpbp.2006.09.010
37. Kim Y-K, Jung H-G, Myint A-M, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104:91-95. PubMed doi:10.1016/j.jad.2007.02.018
38. Knijff EM, Nadine Breunis M, Kupka RW, et al. An imbalance in the production of IL-1B and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9:743-753. PubMed doi:10.1111/j.1399- 5618.2007.00444.x
39. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9:596-602. PubMed doi:10.1111/j.1399-5618.2007.00493.x (Pubitemid 47365627)
40. Cunha AB, Andreazza AC, Gomes FA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258:300-304. PubMed doi:10.1007/s00406-007-0797-0
41. McIntyre RS, Muzina DJ, Kemp DE, et al. Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep. 2008;10:66-72. PubMed doi:10.1007/s11920-008-0012-7
42. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function: glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999;461:107-116. PubMed doi:10.1007/978-0-585- 37970-8-7
43. Pariante CM, Pearce BD, Pisell TL, et al. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology. 1999;140:4359-4366. PubMed doi:10.1210/en.140.9.4359
44. Papiol S, Rosa A, Gutierrez B, et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet. 2004;41:219-223. PubMed doi:10.1136/jmg.2003.012914 (Pubitemid 38333802)
45. Kim SJ, Lee HJ, Koo HG, et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr Genet. 2004;14:165-167. PubMed doi:10.1097/00041444-200409000-00009
46. Pae CU, Lee KU, Han H, et al. Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res. 2004;125:65-68. PubMed doi:10.1016/j.psychres.2003.06.002 (Pubitemid 38210254)
47. Middle F, Jones I, Robertson E, et al. Tumour necrosis factor alpha and bipolar affective puerperal psychosis. Psychiatr Genet. 2000;10:195-198. PubMed doi:10.1097/00041444-200010040-00008 (Pubitemid 32295756)
48. Meira-Lima IV, Pereira AC, Mota GF, et al. Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia. Mol Psychiatry. 2003;8:718-720. PubMed doi:10.1038/sj.mp.4001309
49. Padmos RC, Hillegers MHJ, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65:395-407. PubMed doi:10.1001/archpsyc.65.4.395
50. Lee H-J, Ertley R, Rapoport S, et al. Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem Res. 2008;33:861-866. PubMed doi:10.1007/s11064-007-9526-3
51. Rao JS, Lee HJ, Rapoport SI, et al. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry. 2008;13:585-596. PubMed doi:10.1038/mp.2008.31
52. Maes M, Song C, Lin AH, et al. In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Berl). 1999;143:401-407. PubMed doi:10.1007/s002130050965
53. Bosetti F, Weerasinghe GR, Rosenberger TA, et al. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem. 2003;85:690-696. PubMed (Pubitemid 36531932)
54. Bosetti F, Rintala J, Seemann R, et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry. 2002;7:845-850. PubMed doi:10.1038/sj.mp.4001111
55. Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production. Biol Psychiatry. 2001;50:217-224. PubMed doi:10.1016/S0006-3223(01) 01144-1
56. Ghelardoni S, Tomita YA, Bell JM, et al. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry. 2004;56:248-254. PubMed doi:10.1016/j.biopsych.2004.05.012 (Pubitemid 39092939)
57. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappa B. Brain Res. 2000;857:246-251. PubMed doi:10.1016/S0006-8993(99)02439-7 (Pubitemid 30107811)
58. Pollmacher T, Haack M, Schuld A, et al. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res. 2000;34:369-382. PubMed doi:10.1016/S0022-3956(00)00032-7 (Pubitemid 32101554)
59. Himmerich H, Koethe D, Schuld A, et al. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl). 2005;179:447-451. PubMed doi:10.1007/s00213-004-2038- 9 (Pubitemid 40569047)
60. Lanquillon S, Krieg JC, Bening-Abu-Shach U, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22:370-379. PubMed doi:10.1016/S0893-133X(99)00134-7 (Pubitemid 30105765)
61. Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Disord. 1986;11:227-234. PubMed doi:10.1016/0165-0327(86)90074-1 (Pubitemid 17018802)
62. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord. 1987;13:287-292. PubMed doi:10.1016/0165-0327(87) 90049-8
63. Tsuang MT, Woolson RF, Fleming JA. Causes of death in schizophrenia and manic-depression. Br J Psychiatry. 1980;136:239-242. PubMed doi:10.1192/bjp.136. 3.239
64. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850. PubMed doi:10.1001/archpsyc.58.9.844 (Pubitemid 32979302)
65. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368-373. PubMed doi:10.1111/j.1399-5618.2004.00138.x (Pubitemid 39345287)
66. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979. PubMed doi:10.1056/NEJM199704033361401 (Pubitemid 27152782)
67. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843. PubMed doi:10.1056/NEJM200003233421202
68. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763. PubMed doi:10.1161/01.CIR.0000015464.18023.0A
69. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460-1465. PubMed doi:10.1016/S0735-1097(98)00136-3 (Pubitemid 28273285)
70. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28. PubMed doi:10.1056/NEJMoa042378 (Pubitemid 40075677)
71. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. PubMed doi:10.1161/01.CIR.0000052939.59093.45
72. Fagiolini A, Frank E, Houck PR, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry. 2002;63:528-533. PubMed (Pubitemid 34680363)
73. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207-213. PubMed (Pubitemid 34407079)
74. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824-830. PubMed doi:10.1001/archpsyc.63.7.824
75. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274-280. PubMed (Pubitemid 43764709)
76. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10:342-348. PubMed doi:10.1111/j.1399-5618.2007.00520.x (Pubitemid 351637699)
77. Cassidy F, Ahearn E, Carroll J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-1420. PubMed (Pubitemid 29416540)
78. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002;70(1):19-26. PubMed doi:10.1016/S0165-0327(01)00456-6 (Pubitemid 34756609)
79. Ruzickova M, Slaney C, Garnham J, et al. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 2003;48:458-461. PubMed (Pubitemid 37295203)
80. Das UN. Is obesity an inflammatory condition? (comments appear in Nutrition 2001:17:974-976) Nutrition. 2001;17(11-12):953-966. PubMed doi:10.1016/S0899-9007(01)00672-4
81. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116:1234-1241. PubMed doi:10.1161/CIRCULATIONAHA.107.710509 (Pubitemid 47517534)
82. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200. PubMed doi:10.1210/jc.82.12.4196 (Pubitemid 27525539)
83. Brydon L, Wright CE, O'Donnell K, et al. Stress-induced cytokine responses and central adiposity in young women. Int J Obes. 2007;32:443-450. doi:10.1038/sj.ijo.0803767
84. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'? Curr Diabetes Rev. 2006;2:195-211. PubMed doi:10.2174/157339906776818532
85. Wolford JK, Colligan PB, Gruber JD, et al. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Genet Metab. 2003;80:338-343. PubMed doi:10.1016/j.ymgme.2003.07.003
86. Huth C, Heid IM, Vollmert C, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes. 2006;55:2915-2921. PubMed doi:10.2337/db06-0600
87. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry. 2002;47:742-749. PubMed
88. Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007;153:445. PubMed doi:10.1016/j.ahj.2006.11.005
89. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother. 2007;8:1615-1628. PubMed doi:10.1517/14656566.8.11.1615
90. McIntyre RS, Soczynska JK, Lewis GF, et al. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother. 2006;7:1305-1321. PubMed doi:10.1517/14656566.7.10.1305
91. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med. 2006;68:684-691. PubMed doi:10.1097/01.psy.0000237316.09601.88
92. Kilbourne AM. The burden of general medical conditions in patients with bipolar disorder. Curr Psychiatry Rep. 2005;7:471-477. PubMed doi:10.1007/s11920-005-0069-5
93. McIntyre RS, Konarski JZ, Wilkins K, et al. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache. 2006;46:973-982. PubMed doi:10.1111/j.1526-4610.2006. 00469.x (Pubitemid 43794749)
94. Low NCP, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache. 2003;43:940-949. PubMed doi:10.1046/j.1526-4610.2003.03184.x (Pubitemid 37238648)
95. Zhang J-M, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45:27-37. PubMed doi:10.1097/AIA.0b013e318034194e
96. Peroutka SJ, Price SC, Jones KW. The comorbid association of migraine with osteoarthritis and hypertension: complement C3F and Berkson's bias. Cephalalgia. 1997;17:23-26. PubMed doi:10.1046/j.1468-2982.1997.1701023.x
97. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;64(suppl 2):S9-S15. PubMed
98. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916. PubMed doi:10.1056/NEJM200103223441207
99. Sturmer T, Brenner H, Koenig W, et al. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis. 2004;63:200-205. PubMed doi:10.1136/ard.2003.007674 (Pubitemid 38122141)
100. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807-816. PubMed doi:10.1001/archpsyc.61.8.807
101. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518. PubMed doi:10.1001/jama.264.19.2511
102. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-2610. PubMed doi:10.1001/jama.284.20.2606 (Pubitemid 30844539)
103. Gan WQ, Man SFP, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005;127:558-564. PubMed doi:10.1378/chest.127.2.558
104. Imhof A, Froehlich M, Brenner H, et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 2001;357:763-767. PubMed doi:10.1016/S0140-6736(00)04170-2 (Pubitemid 32217685)
105. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65:1607-1618. PubMed
106. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 Pt 2):S147-S151. PubMed doi:10.1301/nr.2007.dec.S147-S151
107. Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329-2336. PubMed doi:10.1001/archinte.167.21.2329 (Pubitemid 350179528)
108. Kilbourne AM, Rofey DL, McCarthy JF, et al. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord. 2007;9:443-452. PubMed doi:10.1111/j.1399-5618.2007.00386.x
109. Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocialbehavioral model. J Clin Psychiatry. 2006;67:904-915. PubMed (Pubitemid 44047702)
110. Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol. 2005;19(suppl 6):94-101. PubMed doi:10.1177/0269881105058678 (Pubitemid 44567863)
111. Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001;62(6):486-491. PubMed
112. Hamer M, Steptoe A. Association between physical fitness, parasympathetic control, and proinflammatory responses to mental stress. Psychosom Med. 2007;69:660-666. PubMed doi:10.1097/PSY.0b013e318148c4c0 (Pubitemid 47463824)
113. Harvey AG, Schmidt DA, Scarna A, et al. Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry. 2005;162:50-57. PubMed doi:10.1176/appi.ajp.162.1.50 (Pubitemid 40095672)
114. Millar A, Espie CA, Scott J. The sleep of remitted bipolar outpatients: a controlled naturalistic study using actigraphy. J Affect Disord. 2004;80:145-153. PubMed doi:10.1016/S0165-0327(03)00055-7 (Pubitemid 38597137)
115. Motivala SJ, Sarfatti A, Olmos L, et al. Inflammatory markers and sleep disturbance in major depression. Psychosom Med. 2005;6:187-194. doi:10.1097/01.psy.0000149259.72488.09 (Pubitemid 40410952)
116. Irwin MR, Wang M, Campomayor CO, et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med. 2006;166:1756-1762. PubMed doi:10.1001/archinte.166.16.1756 (Pubitemid 44414465)
117. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23:87-94. PubMed doi:10.1002/hup.912
118. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680-684. PubMed doi:10.1038/sj.mp.4001805 (Pubitemid 43989814)
119. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029-1034. PubMed doi:10.1176/appi.ajp.159.6.1029 (Pubitemid 34586950)
120. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90:179-185. PubMed doi:10.1016/j.schres.2006.11.016 (Pubitemid 46177578)
121. Rapaport MH, Delrahim KK, Bresee CJ, et al. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005;57:1594-1596. PubMed doi:10.1016/j.biopsych.2005.02.024
122. Muller N, Ulmschneider M, Scheppach C, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci. 2004;254:14-22. PubMed doi:10.1007/s00406-004-0478-1 (Pubitemid 39310544)
123. Bresee CJ, Delrahim K, Maddux RE, et al. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol. 2006;9:343-348. PubMed doi:10.1017/S1461145705005808 (Pubitemid 43780502)
124. Huang Y, Liu J, Wang LZ, et al. Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons. Acta Pharmacol Sin. 2005;26:952-958. PubMed doi:10.1111/j.1745-7254.2005.00136.x (Pubitemid 41153215)
125. Scali C, Giovannini MG, Prosperi C, et al. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience. 2003;117:909-919. PubMed doi:10.1016/S0306-4522(02)00839-4 (Pubitemid 36332308)
126. Myint AM, Steinbusch HW, Goeghegan L, et al. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation. 2007;14:65-71. PubMed doi:10.1159/000107420 (Pubitemid 47442983)
127. Casolini P, Catalani A, Zuena AR, et al. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res. 2002;68:337-343. PubMed doi:10.1002/jnr.10192 (Pubitemid 34462539)
128. Ferrario A, Fisher AM, Rucker N, et al. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res. 2005;65:9473-9478. PubMed doi:10.1158/0008-5472.CAN-05-1659 (Pubitemid 41508016)
129. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol. 2004;173:2011-2022. PubMed (Pubitemid 38924549)
130. Mao JT, Roth MD, Serio KJ, et al. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res. 2003;9:5835-5841. PubMed
131. Alvarez-Soria MA, Largo R, Santillana J, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis. 2006;65:998-1005. PubMed doi:10.1136/ard.2005. 046920 (Pubitemid 44133260)
132. Hu F, Wang X, Pace TWW, et al. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry. 2005;10:426-428. PubMed doi:10.1038/sj.mp.4001644 (Pubitemid 40646428)
133. Cervantes P, Gelber S, Kin FN, et al. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci. 2001;26:411-416. PubMed (Pubitemid 34081563)
134. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32:675-692. PubMed doi:10.1016/j.neubiorev.2007.10.005
135. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338:171-179. PubMed doi:10.1056/NEJM199801153380307
136. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1355-1361. PubMed doi:10.1016/j.pnpbp.2008.01.006 (Pubitemid 352033661)
137. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol. 2007;157:1275-1277. PubMed doi:10.1111/j.1365-2133.2007.08205.x (Pubitemid 350115684)
138. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29-35. PubMed doi:10.1016/S0140-6736(05) 67763-X (Pubitemid 43038667)
139. Kaufman KR. Etanercept, anticytokines and mania. Int Clin Psychopharmacol. 2005;20:239-241. PubMed doi:10.1097/00004850-200507000-00008
140. Center for Drug Evaluation and Research, US Food and Drug Administration. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). Available at: www.fda.org/CDER/drug/early-comm/TNF-blockers.htm. Accessed April 20, 2009
141. Mori TA, Beilin LJ, Mori TA, et al. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461-467. PubMed doi:10.1007/s11883-004-0087-5
142. White P, Marette A. Is omega-3 key to unlocking inflammation in obesity? Diabetologia. 2006;49:1999-2001. PubMed doi:10.1007/s00125-006-0346-9
143. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. Br J Psychiatry. 2006;188:46-50. PubMed doi:10.1192/bjp.188.1.46 (Pubitemid 43021926)
144. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407-412. PubMed doi:10.1001/archpsyc.56.5.407
145. Keck JPE, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60:1020-1022. PubMed doi:10.1016/j.biopsych.2006.03.056 (Pubitemid 44739928)
146. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res. 1999;33:407-418. PubMed doi:10.1016/S0022-3956(99)00021-7 (Pubitemid 29392689)
147. Krishnan KRR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67:1-8. PubMed doi:10.1097/01.psy.0000151489.36347.18
148. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687-700. PubMed doi:10.1097/chi.0b013e318040b25f
149. Lilic D, Cant AJ, Abinun M, et al. Cytokine production differs in children and adults. Pediatr Res. 1997;42:237-240. PubMed doi:10.1203/00006450- 199708000-00018 (Pubitemid 27311347)
150. Danese A, Moffitt TE, Pariante CM, et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008;65:409-415. PubMed doi:10.1001/archpsyc.65.4.409
151. Pace TWW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163:1630-1633. PubMed doi:10.1176/appi.ajp.163.9.1630 (Pubitemid 44465765)
152. Garno JL, Goldberg JF, Ramirez PM, et al. Impact of childhood abuse on the clinical course of bipolar disorder. (published correction appears in Br J Psychiatry 2005;186:357) Br J Psychiatry. 2005;186:121-125. PubMed doi:10.1192/bjp.186.2.121
153. Leverich GS, McElroy SL, Suppes T, et al. Early physical and sexual abuse associated with an adverse course of bipolar illness. (comment appears in Biol Psychiatry 2002;52:843) Biol Psychiatry. 2002;51:288-297. PubMed doi:10.1016/S0006-3223(01)01239-2
154. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157:683-694. PubMed doi:10.1176/appi.ajp.157. 5.683 (Pubitemid 30249643)
155. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;149:999-1010. PubMed
156. McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33-44. PubMed doi:10.1111/j.1749-6632.1998. tb09546.x